Table 2.
Recent pharmacological options and Cardiovascular Outcome Trials: data regarding the duration of the studies, the inclusion of subjects with diabetes, and the primary outcome vs. control group (↑: increased, ↓: decreased).
| Class | Trial | Duration of the Study (In Years) | Diabetes | Primary Outcome in Drug vs. Control (%) |
|---|---|---|---|---|
| DPP-IVi | SAVOR/TIMI 53 (saxagliptin) |
2.1 | Yes | ↑ 7.3% vs. 7.2% |
| CARMELINA (Linagliptin) |
2.2 | Yes | ↑ 12.4% vs. 12.1% | |
| CAROLINA (linagliptin) |
6.3 | Yes | ↑ 11.8% vs. 12% | |
| TECOS (sitagliptin) |
3 | Yes | ↓ 11.4% vs. 11.6% | |
| EXAMINE (alogliptin) |
1.5 | Yes | ↓ 11.3% vs. 11.8% | |
| SGLT2i | EMPEROR-reduced (empagliflozin) |
1.4 | With/without | ↓ 15.8% vs. 21.0% |
| EMPA-REG (empagliflozin) |
3.1 | Yes | ↓ 37.4% vs. 43.9% | |
| Emperor-presrved (empagliflozin) |
2.4 | With/without | ↓ 13.8% vs. 17.1% | |
| Declare-TIMI (dapagliflozin) |
4.2 | Yes | ↓ 22.6% vs. 24.2% | |
| DAPA-HF (dapagliflozin) |
1.7 | With/without | ↓ 11.6% vs. 15.6% | |
| CANVAS (canagliflozin) |
3.6 | Yes | ↓ 26.9% vs. 31.5% | |
| CREDENCE (canagliflozin) |
2.6 | Yes | ↓ 11.1% vs. 15.5% | |
| VERTIS CV (ertuglifozin) |
3.5 | Yes | n 11.9% vs. 11.9% | |
| SOLOIST-WHF (sotagliflozin) |
0.9 | Yes | ↓ 51.0% vs. 76.3% | |
| SCORED (sotagliflozin) |
1.3 | Yes | ↓ 56% vs. 75% | |
| GLP1-RAs | LEADER (liraglutide) |
3.8 | Yes | ↓ 13% vs. 14.9% |
| REWIND (dulaglutide) |
5.4 | Yes | ↓ 12% vs. 13.4% | |
| HARMONY (albiglutide) |
1.6 | Yes | ↓ 7% vs. 9% | |
| SUSTAIN-6 (semaglutide) |
2.1 | Yes | ↓ 6.6% vs. 8.9% | |
| ELIXA (lixisenatide) |
2.1 | Yes | ↓ 13.4% vs. 13.2% | |
| EXSCEL (exenatide) |
3.2 | Yes | ↓ 11.4% vs. 12.2% | |
| GIP/GLP-1Ra | SUPRASS (terzipatide) |
ongoing | Yes | ongoing |